Innovative Medicines Canada Welcomes Additional Investment by the Federal Government in Research, Clinical Trials and Testing for COVID-19

OTTAWA, ON / ACCESSWIRE / April 23, 2020 / Innovative Medicines Canada (IMC) issued the following statement in response to the federal government’s announcement today of additional funding for research into vaccines and treatments for COVID-19, clinical trials and expanded testing:

“IMC welcomes today’s announcement by the federal government of further investments into research, clinical trials, and expanded testing related to COVID-19. It is an important contribution to the work that is already being undertaken across the country, including by Canada’s innovative pharmaceutical sector.

“IMC looks forward to additional details about how the government plans to invest this additional funding, and we will continue to work closely with all levels of government, the research community and public agencies to develop solutions to address the spread of the virus.”

Learn more about how our member companies are contributing to the fight against COVID-19.

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

For further information:

Sarah Dion-Marquis
Director, Media and Public Relations
Telephone: 613-769-6510
E-mail: sdmarquis@imc-mnc.ca

SOURCE: Innovative Medicines Canada

View source version on accesswire.com:
https://www.accesswire.com/586651/Innovative-Medicines-Canada-Welcomes-Additional-Investment-by-the-Federal-Government-in-Research-Clinical-Trials-and-Testing-for-COVID-19